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Introduction
In recent times, the once unrealistic
aspiration of long successful aging has
been widely portrayed as a reachable
target for both the individual and
society. Unfortunately, the overall
increasing age of the world population
is accompanied by a rise in diseases
including cardiovascular and neurode-
generative disease, cancer and immune disorders (North &
Sinclair, 2012). The increase of the life expectancy in
industrialized, but also developing countries results primarily
fromhighernumbersofindividualsagedabove65.Forexample,
the number of Americans with an age above 65 is expected to
double from 2000 to 2030 (Wang et al, 2010a) and in Europe, by
2050, there will be 48 million fewer 15–64 year-old people and
58 million more above 65 years of age. This undoubtedly will
lead to an increase in age-associated diseases worldwide.
Despite the accumulating evidence that senescence is a major
risk factor for human diseases, little is known about the
molecular mechanisms that link the aging process to diseases.
Research on aging has mostly been restricted to relatively short-
lived organisms such as the small nematode Caenorhabditis
elegans. With a normal life span of 21 days and the possibility to
study short- or long-lived mutants, the worm has been an ideal
model to identify genetic pathways that modulate aging.
Signiﬁcantly, most of these pathways are evolutionary con-
served across species, including mammals. The insulin/insulin-
like growth factor (IGF) signalling and the ‘target of rapamycin’
TOR signalling pathways have been studied in depth. Con-
vergent ﬁndings show that inhibition of these pathways can
extend longevity in model organisms (Kenyon, 2010). Also,
majorinterventionsthatextendlifespanengageeitherorbothof
these pathways. For example, the TOR signalling cascade is
involved in the extended life span due to dietary restriction,
which appears to be universally associated with longevity in
several organisms including mammals (Blagosklonny et al,
2009). Other relevant processes involved in aging include
mitochondrial electron transport and respiration (Hughes &
Hekimi, 2011; Moslehi et al, 2012).
A key component of the aging process is cellular senescence.
Senescence does not occur simultaneously in all cells within a
tissue, but involves irreversible proliferative arrest of damaged
or dysfunctional cells (Rodier & Campisi, 2011). This con-
tributes to restrict malignant progression of tumours, but also
leads to accumulation of senescent cells within tissues.
Senescent cells are not entirely quiescent, and recent evidence
shows that they can actively promote aging and tissue damage
(Baker et al, 2011). Targeted removal of senescent cells can
delay the appearance of age-related phenotypes and organ
dysfunction. Cell senescence is linked to complex changes
in cellular morphology, structure and function (Rodier &
Campisi, 2011). Major structural changes such as loss of the
ends of the chromosomes (telomere erosion) accompany the
irreversible growth arrest in senescent cells. Telomere erosion
can be counteracted by the activity of telomerase, which is
OPEN
ACCESS
Review Series
small RNAs
Review
MicroRNAs and aging
(1) Institute for Cardiovascular Regeneration, Centre of Molecular Medicine,
Goethe University Frankfurt, Frankfurt, Germany
(2) German Center for Cardiovascular Research (DZHK), Frankfurt, Germany
(3) German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
*Corresponding author: Tel: þ49 69 6301 5158; Fax: þ49 69 6301 7113;
E-mail: dimmeler@em.uni-frankfurt.de
Aging is a complex process that is linked to an increased incidence of major
diseases such as cardiovascular and neurodegenerative disease, but also cancer
andimmunedisorders.MicroRNAs(miRNAs)aresmallnon-codingRNAs,whichpost-
transcriptionally control gene expression by inhibiting translation or inducing
degradation of targeted mRNAs. MiRNAs target up to hundreds of mRNAs, thereby
modulating gene expression patterns. Many miRNAs appear to be dysregulated
during cellular senescence, aging and disease. However, only few miRNAs have been
so far linked to age-related changes in cellular and organ functions. The present
article will discuss these ﬁndings, speciﬁcally focusing on the cardiovascular and
neurological systems.
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cells, and can reverse cellular aging in somatic cells when
overexpressed (Boccardi & Herbig, 2012; Martinez & Blasco,
2011). Interestingly, telomere dysfunction has also been linked
to metabolic changes suggesting an interplay between these
two processes (Moslehi et al, 2012). Additional factors involve
changes in protein processing, gene expression and miRNAs. As
the factors leading to cell senescence become increasingly clear,
it appears that dysfunction of the same pathways can occur
in disease states. Several microRNAs (miRNAs) are involved in
the regulation of pathways involved in cellular senescence
and have effects on cell cycle progression. In addition, major
changes in miRNA expression are involved in disease
phenotypes in model organisms and have been found in tissues
from human disease. The present article will discuss these
ﬁndings, particularly focusing on the regulation and function of
age-regulated miRNAs in cardiovascular and neurodegenerative
diseases.
MicroRNAs
MicroRNAs (miRNAs, miRs) are small, non-coding RNAs that
post-transcriptionally control gene expression by blocking
translation or inducing degradation of the targeted mRNA
(for review see Bartel, 2009). In general, miRs are transcribed as
primary transcripts by the RNA polymerase II. This primary
transcript is further processed by the endonucleases Drosha and
Dicer, resulting in the generation of a short RNA duplex. One
strand of the duplex is loaded into the RNA-induced silencing
complex (RISC) to bind to the target mRNA, whereas the other
strand is usually (but not always) degraded. The regulation of
miRNA biosynthesis and biochemical mode of action have been
reviewed in detail elsewhere (e.g. see Ambros, 2004; Bartel,
2009; Bauersachs & Thum, 2011).
The small non-coding miRNA lin-4 was ﬁrst described
in Caenorhabditis elegans as a regulatory gene essential for
the transition through all the larval stages. During development,
lin-4 post-transcriptionally targets the nuclear factor LIN-14 and
thus controls post-embryonic cell lineage patterns (Lee et al,
1993). Since then, almost 2000 miRNAs have been identiﬁed in
mammals. MiRNAs play key roles in regulating development
and tissue homeostasis, and de-regulation of miRNAs is
implicated in the pathophysiology of various diseases such as
cancer, cardiovascular, neurological and metabolic diseases
(Bonauer etal, 2010; Gascon & Gao,2012; He ´bert &De Strooper,
2009; Iorio & Croce, 2012; Thum, 2012). Based on the
identiﬁcation of disease-regulated miRNAs, the targeting of
miRNAs as a therapeutic approach was tested in experimental
disease models, and particularly the inhibition of miRNAs by
anti-sense ‘anti-miRs’ or ‘antagomirs’ was shown to improve
disease states in mouse models (Thum, 2012; van Rooij et al,
2008). Importantly, locked nucleic acid inhibitors directed
against miR-122 were successfully used to treat hepatitis in non-
human primates in a Phase II clinical trial (NCT01200420;
Lindow & Kauppinen, 2012), suggesting that modulation of
miRNAs might be a therapeutic option. De-regulation of
miRNAs has also been shown during cellular senescence and
aging in vivo. We will summarize the current knowledge
regarding the involvement of miRNAs in aging, with a focus on
the regulation and function of age-regulated miRNAs in
cardiovascular and neurodegenerative diseases.
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Glossary
Alzheimer’s disease
Age-related neurodegenerative disease, characterized pathologically by
the accumulation of protein aggregates known as plaques and tangles
consistingmainlyoftheproteinsamyloidbetaandphosphorylatedtau.The
main symptoms are memory loss and reduced cognitive function.
Anti-miRs, antagomirs
Backbone-modified antisense oligomers complementary to microRNAs,
which block their function.
Atherosclerosis
Conditionin whichfatty materialaccumulates inthearterywall,whichcan
restrict blood flow.
Calorie restriction
Reduced calorie intake diet with the aim to improve health and slow down
the aging process.
Frontotemporal dementia
Early onset neurodegenerative disease caused by degeneration of the
frontal and often the temporal lobes of the cerebral cortex. Symptoms vary
depending on the brain regions affected.
Hutchinson–Gilford progeria syndrome
Rare genetic disease caused by progerin, a truncated version of the lamin A
protein. Clinical manifestations include the appearance of aging beginning
in childhood.
Locked nucleic acid (LNA) technology
Backbone modification of nucleic acids that locks the sugar moieties into a
single constrainedconformation, makingtheoligomersthey are associated
with nuclease-resistant.
MicroRNA
Small non-coding RNA molecule that controls gene expression by targeting
messenger RNAs.
Parkinson’s disease
Age-related neurodegenerative disease, characterized pathologically by
the accumulation of protein aggregates in the brain, mainly composed of
alpha-synuclein known as Lewy bodies. The main symptoms are reduced
motor skills and movement defects.
Reactive oxygen species (ROS)
Chemically reactive oxygen-containing molecules. ROS levels increase
in a cell during oxidative stress and cause damage to DNA, proteins and
lipids.
RNA-induced silencing complex (RISC)
Ribonucleoprotein complex containing a small RNA such as a
microRNA, which guides the RISC to complementary target messenger
RNAs.
Senescence
The endogenous and hereditary process of accumulative changes
in the passage of time resulting in functional deterioration and/or
death.
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Aging is a biological process highly regulated by multiple
evolutionary conserved mechanisms. Most of the involved
signalling pathways converge in nutrient sensors that control
intracellular metabolism and gene expression (Bano et al, 2011;
Kenyon, 2010). C. elegans lifespan is regulated by Insulin/IGF-1
signalling (IIS; reviewed in Kenyon, 2010). DAF-2 (an insulin
receptor-like protein) regulates the expression of the transcrip-
tion factors abnormal dauer formation-16 (DAF-16) and heat
shock factor-1 (HSF-1; Hsu et al, 2003). Loss of daf-2 function
increases lifespan, while gain of daf-16 function is required for
extended survival, which can be antagonized by daf-2 in wild-
type C. elegans (Lin et al, 2001). More recent evidence has
showed that miRNAs can contribute in the regulation of
longevity. In C. elegans, loss-of-function of the heterochronic
gene lin-4 signiﬁcantly shortens the lifespan, whereas lin-4
overexpression extends the survival of nematodes. As demon-
strated by epistasis analysis, this lifespan modulation requires
the lin-4 target gene lin-14 (Boehm & Slack, 2005). Although it is
still unclear by which mechanism the lin-4/lin-14 axis controls
aging, these two temporal regulators of development genetically
interact with some components of the Insulin/IGF-1 signalling
pathways. In fact, lin-14 loss-of-function is unable to affect the
survival of the long-lived Insulin/IGF-1 deﬁcient daf-2 (e1370)
mutant, but it requires the downstream target DAF-16/FOXO
to lengthen C. elegans lifespan. Although most miRNAs are
dispensable for normal lifespan of model organisms, some other
miRNAs can affect nematode longevity through DAF-16/FOXO-
mediated gene transcription (de Lencastre et al, 2010). Among
them, miR-71 remarkably coordinates longevity in a cell-non-
autonomous manner. In wild-type C. elegans, miR-71 loss-of-
function signiﬁcantly decreases resistance to both heat shock
and oxidative stress. Interestingly, miR-71 abolishesthe lifespan
extension of germline-less animals. Thus, along with secreted
signals from the reproductive system, miR-71 likely targets
unknown factors in the nervous system and, as a result,
coordinates the nuclear redistribution of DAF-16/FOXO in the
intestine, the main adipose tissue in nematodes (Boulias &
Horvitz, 2012).
Meanwhile various miRNAs have been identiﬁed by micro-
arrays or deep sequencing, which are regulated during
C. elegans aging (Ibanez-Ventoso et al, 2006; Kato et al,
2011). Speciﬁcally, let-7 is downregulated with advanced aging
(Ibanez-Ventoso et al, 2006; Kato et al, 2011), which is
consistent with the known function of let-7 in the suppression
of the steroid hormone receptor daf-12 and therefore life span.
Interestingly, in mice, let-7 targets various components of the
Insulin/IGF-1/mTOR pathwaythrough theRNA-binding protein
Lin28 (Zhu et al, 2011), with important consequences for
glucose metabolism. The muscle-enriched miR-1 also declined
during aging (Ibanez-Ventoso et al, 2006). Upregulated miRNAs
include miR-71, miR-238, miR-239 and miR-246 (de Lencastre
et al, 2010). Whereas deletion of miR-71, miR-238 and miR-246
decreased life span, deletion of miR-239 had the opposite effect
and extended life span (de Lencastre et al, 2010). Another age-
induced miRNA, namely miR-34, did not affect C. elegans life
span in one study (de Lencastre et al, 2010) but its inhibition
enhanced life span by regulating autophagy in another study
(Yang et al, 2011). In ﬂies, loss of miR-34 triggered a decline in
survival (Liu et al, 2012).
Several miRNA expression proﬁles have been generated to
determinechangesduringaginginmammaliancellsandtissues.
While main endpoints of miRNA changes in C. elegans included
life span and metabolic modiﬁcations, studies in mammalian
systems have focused on speciﬁc tissues and systemic
alterations. For example, a recent study in mouse models of
senescence suggested that miR-29 targets type IV collagen genes
(Takahashi et al, 2012). Type IV collagen is important for the
maintenance of the structure of extracellular matrix. Increases
in miR-29 in elderly mouse tissues were shown to decrease
type IV collagen expression and weaken the basement
membranes in elderly tissues.
In humans, comparisons of miRNA expression between
peripheral blood mononuclear cells of young versus old
individuals revealed the downregulation of various miRNAs,
among which two – namely miR-24 and miR-221 – were
validated in a cohort of older individuals (Noren Hooten et al,
2010). Other groups studied miRNA expression during culture-
inducedsenescenceandshowedthatmembersofthemiR-17–92
cluster, namely miR-17, miR-19b, miR-20a and miR-106a are
downregulated in several cell types (Hackl et al, 2010). In
addition, miRNA proﬁles have been generated to compare
aortas from young versus old mice (Boon et al, 2011), in
senescent cultured humanumbilical endothelial cells (Menghini
et al, 2009), human and macaque prefrontal cortex samples
during post-natal development and aging (Somel et al, 2010) as
well as in neurodegenerative diseases (see below). Never-
theless,onlyfewmiRNAssofarhavebeendirectlylinkedtoage-
related changes in cellular and organ functions. However, many
have been directly connected with disease states and it is
yet unclear whether changes in miRNA proﬁles are mostly
involved in the onset of pathological changes or rather mark the
end stage of the senescence process resulting in organ aging
and dysfunction.
MiRNAs and age-related cardiovascular diseases
Aging is the predominant risk factor for developing cardio-
vascular diseases (North & Sinclair, 2012). In the vasculature,
aging impairs the atheroprotective effects of the endothelium
as evidenced by reduced nitric oxide bioavailability and
increased NFkB activation leading to endothelial inﬂammation
(Pierce et al, 2009). Additionally, the smooth muscle cell
phenotype is changed towards a pro-proliferative and pro-
invasive characteristic and the composition of the extracellular
matrix is signiﬁcantly modulated (Wang et al, 2010a).
Together, these changes result in arterial remodelling char-
acterized by thickening of the intima and reduced arterial
dilation capacity (Fig 1). It is considered that the changes
in cellular functions and extracellular matrix during aging
make the atrial wall susceptible for atherosclerotic lesion
progression.
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systems additionally contributes to the development of heart
failure (Strait & Lakatta, 2012). Thus, 90% of all heart failure
deaths occur in individuals older than 70 (Strait & Lakatta,
2012). Aging is associated with an increase in ﬁbrosis and
contributes to diastolic dysfunction, which typically occurs in
the elderly. In addition, aging contributes to a signiﬁcantly
worse outcome in patients with ischemic diseases such as acute
myocardial infarction. The impaired neovascularization capa-
city during aging and the reduced function of vasculoprotective,
proangiogenic cells and progenitor cells, which help to repair
the vasculature and the heart after injury, may contribute to the
age-associated worsening of recovery after critical ischemia
(Dimmeler & Leri, 2008).
MiRNAs in vascular aging
Several studies have addressed the regulation of miRNAs during
culture-induced senescence of vascular cells (Hackl et al, 2010;
Menghini et al, 2009; Olivieri et al, 2012) or in vessels that were
isolated from aged mice (Boon et al, 2011). In cell culture
studies, human umbilical venous endothelial cells were
continuously cultured (population doubling time: 44) and
miRNAs were detectedin these senescent endothelial cells using
microarrays. miR-21, miR-216, miR-217, miR-181b, miR-31b,
miR-34a were among the conﬁrmed upregulated miRs (Men-
ghini et al, 2009), whereas members of the miR-17–92 cluster
were downregulated (Hackl et al, 2010). In whole aortas of
aged mice, the inﬂammation- and haematopoiesis-associated
miR-146, miR-142-3p and miR-223 and the matrix-regulating
miR-29 family were signiﬁcantly increased, while other
miRNAs, which were highly expressed in senescent endothelial
cells, such as miR-181c/d and miR-31, were downregulated
(Boon et al, 2011). These differences between the proﬁles
of cultured endothelial cells and entire vessels likely reﬂect
the different cellular compositions since in whole vessels
smooth muscle cells and invaded inﬂammatory cells, but not
endothelial cells are the predominant cell types. Therefore,
whole tissue miRNA proﬁles have to be interpreted with
caution, since the differential expression of miRNAs in
selected cell types may be hidden behind the total changes in
the tissue. Several of the regulated miRNAs have meanwhile
been investigated in more detail (Fig 1).
miR-29 in age-associated vascular remodelling
In aortas from young versus old mice, members of the miR-29
family, namely miR-29a, miR-29b and miR-29c are upregulated
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Figure 1. Regulation of miRNAs during cardiovascular aging. The impact of aging on the vasculature and the heart is summarized. MiRNAs that are regulated
during aging of the vasculature or the heart are shown with arrows indicating up- or downregulation during aging in comparison to young tissue. Only validated
targets are shown.
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members is consistent with the upregulation of this miRNA
family in several tissues of Zmpste24
 /  mice, a model for
Hutchinson–Gilford progeria that exhibits accelerated aging
and recapitulates many symptoms of normal aging (Ugalde
et al, 2011). In addition, miR-29a was among the signiﬁcantly
increased miRNAs in cultured senescent endothelial cells
(Menghini et al, 2009; Olivieri et al, 2012), and miR-29 was
shown to contribute to senescence in cervical carcinoma
cells (Martinez et al, 2011). The miR-29 family is well known
to repress matrix proteins in the heart and liver and the
increased expression of miR-29 family members in the aorta of
aged mice was associated with a decline of matrix protein
expression such as collagens and elastin (Boon et al, 2011).
Since a reduction of extracellular matrix is considered to
contribute to aneurysm formation, which is a typical age-
associated vascular disease, several groups studied whether
miR-29 inhibition could be exploited to improve the structural
integrity of the vascular wall. Indeed, inhibition of miR-29
byanti-miRsenhancedmatrixproteinexpressioninAngiotensin
II-induced aneurysms in aged mice as well as in genetic models
of aneurysm formation (Boon et al, 2011; Maegdefessel et al,
2012; Merk et al, 2012; Zhang et al, 2012a). Of note, systemic
inhibition of miR-29 may cause ﬁbrosis or tumour growth,
therefore warranting a local delivery strategy for putative
therapeutic development.
The mechanism by which miR-29 is increased during aging is
not entirely clear. Aging induces the primary miR-29b1-29a
cluster (which encodes miR-29b and miR-29c), whereas the
expression of the primary miR-29b2-29c cluster (encoding miR-
29b and miR-29c) is not regulated in aged vessels (Boon et al,
2011). However, mature miR-29a, miR-29b and miR-29c were
increased in the aorta of aged mice (Boon et al, 2011) and in
Zmpste24-null mice, a mouse model of Hutchinson–Gilford
progeria (Ugalde et al, 2011), indicating that age-induced
upregulated involves transcriptional and post-transcriptional
mechanisms (Boon & Dimmeler, 2011).
miR-34a in vascular aging
MiR-34a is not only increased during culture-induced endothe-
lial cell senescence (Ito et al, 2010; Menghini et al, 2009; Olivieri
et al, 2012) but also in different organs of aged mice (Ito et al,
2010; Li et al, 2011b). miR-34a expression was augmented in
cultured endothelial progenitor cells and bone marrow-derived
pro-angiogenic cells that were isolated from older patients with
coronary artery disease or from aged mice (Tabuchi et al, 2012;
Xu et al, 2012) and during C. elegans aging (de Lencastre et al,
2010) suggesting conserved age-induced expression of this
miRNA. Overexpression of miR-34a induced senescence and
inhibited proliferation of endothelial cells (Ito et al, 2010) and
pro-angiogenic cultured endothelial progenitor cells (Zhao et al,
2010). MiR-34 is transactivated by p53 and promotes apoptosis
(Chang et al, 2007). Indeed, miR-34a also induced cell death
of bone marrow-derived proangiogenic cells (Xu et al, 2012),
whereas inhibition of miR-34a reduced cell death of bone
marrow-derived pro-angiogenic cells in vitro and augmented
the capacity of the cells to improve cardiac function after acute
myocardial infarction (Xu et al, 2012). In endothelial cells and
endothelial progenitor cells, the class III histone deacetylase
SIRT1 was shown to be the predominant target of miR-34a (Ito
et al, 2010; Tabuchi et al, 2012; Zhao et al, 2010). SIRT1 is
essential for endothelial cell functions and neovascularization
after ischemia (Potente et al, 2007) and has been considered to
reduce cellular senescence and enhance longevity (Maxwell
et al, 2012). The downregulation of SIRT1 by miR-34a is in line
with the detrimental effects of miR-34a on endothelial and
progenitor cells functions. In addition, miR-34a inhibition
enhanced the expression of the anti-apoptotic protein Bcl-2
and several cell cycle regulators such as Cdk4 and Cyclin D2
in freshly isolated bone marrow-derived proangiogenic cells
(Xu et al, 2012).
The mechanism underlying the increase in miR-34a expres-
sion in aging has not been elucidated. It is known that p53
induces the expression of the transcripts encoding miR-34
family members and promotes miR-34a processing (Chang et al,
2007; He et al, 2007; Tarasov et al, 2007). But the expression of
miR-34 can be increased independent of p53 (Christoffersen
et al, 2010) and is also regulated by DNA methylation of CpG
islands of the miR-34 promoters (Lodygin et al, 2008). However,
DNA methylation of the promoter of miR-34a of pro-angiogenic
cells was not changed during aging (Xu et al, 2012). Given the
known involvement of p53 in age-associated pathways (Sahin &
DePinho, 2012), one may speculate that p53 might mediate
the age-induced upregulation of miR-34a.
miR-146 in endothelial cell senescence
miR-146 represents an inﬂammation-associated miRNA that
was shown to be augmented in senescent ﬁbroblasts (Bhaumik
et al, 2009). miR-146 was profoundly increased in senescent
cultured umbilical venous and different aortic endothelial cells
and the increased expression was linked to the senescence-
associated secretory phenotype (Olivieri et al, 2012). Thereby,
an increase in senescence was associated with a decrease in
IRAK, which controls the inﬂammatory response, whereas
inhibition of miR-146 increased IRAK expression (Olivieri et al,
2012). Whileithasrecentlybeen conﬁrmedthatmiR-146 targets
IRAK1 in the heart, this resulted in protection against immune
hyper-responsiveness during ischemia/reperfusion injury
(Chassin et al, 2012). In addition, other groups reported that
miR-146 was not regulated (Hackl et al, 2010) or was even
signiﬁcantly decreased in senescent umbilical venous endothe-
lial cells (Vasa-Nicotera et al, 2011). In the latter study, miR-
146a overexpression in endothelial cells reduced the NADPH
oxidase NOX4, suggesting that reduced miR-146a expression
might increase reactive oxygen species generation during
endothelial cells senescence (Vasa-Nicotera et al, 2011). The
reason for the discrepant ﬁndings showing either an increased
or decreased expression of miR-146a during endothelial cell
senescence are unclear, however, one may speculate that miR-
146 may be upregulated as a feed-back mechanism during
prolonged culture to suppress the senescence-associated
secretory phenotype. in vivo experiments are now warranted
to determine the relevance of the regulation of miR-146a during
vascular aging.
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miR-217 was identiﬁed as the most profoundly regulated
miRNAs in senescent human umbilical endothelial cells
(Menghini et al, 2009). Its overexpression signiﬁcantly sup-
pressedSIRT1,whichplaysacrucialroleinendothelialcellsand
is also targeted by the age-induced miR-34a (see above). The
upregulation of miR-217 was associated with a downregulation
of SIRT1 and further increased eNOS acetylation and reduced
eNOS protein expression in vitro (Menghini et al, 2009).
Furthermore, miR-217 levels were inversely correlated with
SIRT1 and eNOS expression in human atherosclerotic plaques
(Menghini et al, 2009) suggesting that these pathways are
functional under pathophysiological conditions.
Other senescence-associated vascular miRNAs
Some members of the miR-17–92 cluster including miR-17, miR-
20a and miR-106a were signiﬁcantly downregulated in senes-
cent human umbilical endothelial cells (Hackl et al, 2010),
whereas in another screen miR-17-5p expression was increased
(Menghini et al, 2009). Since the members of the miR-17–92a
family play distinct roles in endothelial cells, including pro-
proliferative activity of miR-17/miR-20 but anti-angiogenic
function of miR-17, miR-20 and miR-92a (Doebele et al, 2010)
and were shown to reduce oncogene-induced senescence in
tumour cells (Hong et al, 2010), further studies are required to
elucidate the regulation and function of the individual family
members during vascular aging and senescence. In addition,
oxidative stress can induce miR-200c (Magenta et al, 2011;
Olivieri et al, 2012) and its overexpression induces endothelial
cell senescence in vitro (Magenta et al, 2011).
MiRNAs in cardiac aging
In contrast to the vasculature, little is known regarding the
regulation of miRNAs during cardiac aging. Although miRNA
proﬁling of hearts from old versus young mice showed profound
regulation of various miRNAs and miRNA clusters, only the
upregulation of miR-21 has been validated in this study (Zhang
et al, 2012b). miR-21 is known for its proﬁbrotic activity (Thum
et al, 2008), which may well ﬁt in the context of cardiac aging,
but the precise function during cardiac aging remains to be
determined.
A second proﬁle in functionally well-characterized aged
mice revealed that miR-22 and miR-24 are profoundly induced
during life span (Jazbutyte et al, 2012). The function of miR-22
has been further characterized in detail and loss-and
gain of function studies conﬁrmed that miR-22 induces
senescence and promotes migration of cardiac ﬁbroblasts
(Jazbutyte et al, 2012). These ﬁndings are consistent with
studies of others showing that miR-22 induces senescence
in tumour cells (Xu et al, 2011). The effects of miR-22 in
cardiac ﬁbroblasts were partially mediated by the targeting
of mimecan/osteoglycine (OGN), which is a secretory
protein that was initially shown to control bone formation,
but also is expressed in cardiac ﬁbroblasts and smooth muscle
cells (Jazbutyte et al, 2012). However, miR-22 additionally
induces hypertrophy and may act via other known targets such
as SIRT1.
Furthermore, van Almen et al. showed that members of
the miR-17–92a cluster, speciﬁcally miR-18 and miR-19, were
decreased in mouse strains, which are characterized by age-
induced cardiac ﬁbrosis and dysfunction (van Almen et al,
2011). The authors further conﬁrmed that the previously
identiﬁed miR-18 and miR-19 targets thrombospondin-1 and
connective tissue growth factor are increased in heart failure-
prone aged mice and the inverse correlation of the miRNAs and
the targets was conﬁrmed in human samples (van Almen et al,
2011). In vitro studies further explored the function of miR-18
and miR-19 and showed that both miRNAs suppress collagen
expression in cardiac myocytes (van Almen et al, 2011).
Although the mechanism by which these miRNAs regulate
collagen expression has not been fully elucidated, these ﬁndings
may provide a link between the downregulation of miR-18/miR-
19 with age-induced ﬁbrosis. Finally, miRNAs such as miR-133
can also modulate age-independent cardiac conditions, includ-
ing hypertrophy (Care et al, 2007) and it may be interesting to
study the impact of hypertrophy-regulation miRNAs in cardiac
remodelling during aging.
MiRNAs and age-related neurodegenerative
diseases
Aging induces multiple cellular and functional changes in the
brain that are partially compensated by adaptive neuroprotec-
tive and neurorestorative processes. Typical age-associated
degenerative changes include abnormal and dysfunctional
axons and neuritis, a decline in the neurotransmitter network,
and presence of amyloid plaques and lipofusin around blood
vessels. Some of these changes are analogous to changes
observed in neurological diseases, with the notable exception of
neuronal loss (Morrison & Hof, 1997). The burden of
neurodegenerative disorders is progressively growing as the
proportion of older people increases. According to the WHO, by
2040, neurodegenerative diseases are going to be the second
leading cause of death after cardiovascular diseases. The
prevalence of dementia cases will increase by 100% in
developed countries and by up to 300% in newly industrialized
countries (Ferri et al, 2005). Alzheimer’s disease is the most
prominent neurodegenerative disorder. However, an increasing
number of people are diagnosed with mixed forms of dementia,
vascular dementia and dementia with Lewy bodies. Notably
a growing number of Parkinson’s disease patients develop
dementia as the disease spreads and progresses (Perez et al,
2012). Despite age being the most prominent risk factor for
neurodegenerative diseases, the mechanisms and molecular
targets involved are unknown. MiRNAs have been implicated
both in the aging program and in disease of the nervous system.
Moreover, it is becoming clear that miRNAs regulate physio-
logical processes such as synaptic plasticity, learning and
memory (Table 1).
Proﬁling of tissue samples provided ﬁrst evidence for
regulation of miRNAs in the aging brain. In samples obtained
from human prefrontal cortex, Somel et al. showed an
age-associated upregulation of miR-34, miR-33b, miR-181 and
www.embomolmed.org Review
Stefanie Dimmeler and Pierluigi Nicotera
EMBO Mol Med (2013) 5, 180–190  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 185miR-1271(Someletal,2010).Inmacaquebrainsamples,similar
patterns were observed including additionally miR-29b (Somel
et al, 2010). In mice, age-associated increase in miR-30d, miR-
34a, miR-468, miR-669b and miR-709 were observed in brain
and liver tissue, whereas miR-22, miR-101a, miR-720, miR-721
were only increased in brain but not in livers of aged mice (Li
et al, 2011a). Several of the increased miRNAs in the brain were
predicted to control mitochondrial function, which is not
surprising given that deregulation of mitochondrial function is a
major factor in age-induced processes (Larsson, 2010). Main-
tenance of mitochondrial oxidative metabolism and energy
production is particularly relevant at nerve endings, where
mitochondria are essential to maintain protein turnover and
exo-endocytotic processes at active synapses (Li et al, 2004).
Long-term changes in synaptic strength also involve a rapid
protein turnover. Therefore translational control at synapses
is very important for structural plasticity. For example, the
RISC protein MOV10 is rapidly degraded at synapses in an
activity-dependent manner. This in turn causes several
mRNAs to enter polysomes and drive protein expression
(Banerjee et al, 2009). Evidence is accumulating that miRNAs
have a signiﬁcant role in modulating synaptic functional and
structural plasticity (Lee et al, 2012; Lippi et al, 2011). It is
therefore conceivable that altered local translational regulation
may compromise learning and memory in dementia and other
neurodegenerative disorders.
Initial evidence for the role of miRNAs in neurodegenerative
diseases came from Schaefer et al (2007), who showed that
conditional Purkinje cell-speciﬁc ablation of the key miRNA-
generating enzyme Dicer resulted in cell death. Lack of Dicer
was associated with progressive loss of miRNAs, cerebellar
degeneration and development of ataxia in vivo. More recent
ﬁndings conﬁrm an important role for miRNA in age-associated
neurodegeneration. Ablation of Dicer in adult forebrain
caused abnormal tau hyperphosphorylation and neurodegen-
eration as observed in Alzheimer’s disease brain. In view of
these and other ﬁndings there are a number of studies of
miRNA proﬁling in brain samples obtained from patients with
neurodegenerative diseases. For example, miR-9, miR-125b and
miR-146 are increased (Sethi & Lukiw, 2009) in temporal
lobes neocortexes and hippocampal regions from Alzheimer’s
patients. Lukiw et al, also reported a signiﬁcant upregulation of
miR-9 and miR-128 compared to age-matched healthy adults
(Lukiw, 2007). Various miRNAs are dysregulated in sporadic
Alzheimer’s disease patients according to a miRNA array
(He ´bert et al, 2008).
miR-29 in Alzheimer’s disease
Evidence that loss of the miR-29a/b-1 cluster is linked to
sporadic Alzheimer’s disease was provided by He ´bert et al
(2008). The study investigated possible regulators of the
BACE1/b-secretase. BACE1 or APP may conceivably contribute
to Ab in sporadic Alzheimer’s disease cases. BACE-1 processing
of APP is essential to initiate Ab generation, which is then
promoted by the g-secretase. MiRNAs that are potentially
involved in the control of BACE1 expression (miR-29a, 29-b1)
were found to be downregulated in brains of Alzheimer’s
patients that also showed high BACE1 levels. Along the same
lines, these authors identiﬁed miR-20a, miR-17-5p and miR-
106b as regulators of the Amyloid precursor protein (APP;
He ´bert et al, 2008, 2009).
Subsequent studies have found no genetic association of the
genetic variants of the miR-29 clusters with Alzheimer’s disease
(Bettens et al, 2009). However, the lack of genetic variants does
not rule out that miR-29 cluster downregulation modulates
BACE-1expressionandAPPprocessing.Also,themiR-29cluster
has other important roles in the brain that may be relevant to
aging and disease. For example, expression levels of miR-29
affect dendritic spine remodelling by targeting the ARP2/3 actin
nucleation complex. This is especially important for structural
neuronalplasticity (Lippietal, 2011).Interestingly, thedecrease
in miR-29 expression in diseased brains contrasts with the
increase in miR-29 expression levels in other tissues during
aging and the described role of miR-29 in mediating cellular
senescence (see chapter 3).
miR-34 in neurodegeneration
Levels of the miR-34 family change during aging in model
organisms, mice and humans (Liu et al, 2012; Zovoilis et al,
2011). Loss of miR-34 is linked to accelerated aging and
neurodegeneration in Drosophila. Interestingly, expression and
processing of miR-34 varies with age in Drosophila and targets
E74A. However, E74A has opposite effects on animal ﬁtness
during different life stages (known as antagonistic pleiotropy)
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Table 1. Regulation of miRNAs during neural aging and neurodegenerative age-associated diseases
miRNA Targets Functions
miR-29 BACE1
ARP2/3
Loss of miR-29 linked to sporadic Alzheimer
miR-29 affects spine remodelling
miR-34
Drosophila
Mice
E74A (Drosophila)
SIRT1
Bcl-2
Loss of miR-34 associated with accelerated aging in Drosophila
Inhibition of miR-34c improves memory function in aged mice
miR-107 BACE1
Progranulin
Levels are reduced in Alzheimer and traumatic brain injury
May be linked to fronto-temporal dementia
Let-7 Hmga2
Lin-28
Imp
Controls neural stem cell functions and aging of the stem cell niche
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point at different regulatory roles for the different members
of the miR-34 family. MiR-34c (but not miR-34a and miR-34b)
is highly enriched in hippocampal regions and its expression
is further upregulated by aging (24 months old mice), in
mice models of amyloidosis (12 months APP/PS1-21 mice)
and in Alzheimer’s disease patients (Zovoilis et al, 2011).
Targeting the miR-34 seed in APP/PS1-21 mice (were miR-34c
is the predominant species) rescued learning dysfunction
in mouse models (Zovoilis et al, 2011). One major target for
miR-34c seems to be SIRT1 (Zovoilis et al, 2011). Decreased
SIRT1 levels cause memory impairment and reducing elevated
miR-34c levels in mice restored memory function in aged mice
(Zovoilis et al, 2011). Given the multiple controls of autophagy
and indirectly mitochondrial homeostasis, this seems a very
promising target to achieve neuroprotection.
MiR-34a is upregulated in the cerebral cortex of other
Alzheimer mouse models including the APPswe/PSDE9 mice.
Calorie restriction reduces miR-34a (and levels of miR-30e and
miR-181a
 ) levels in hippocampus and cortex in aged mice.
Decline of miRs was associated with increased Bcl-2 expression
in aged mice after calorie restriction (Khanna et al, 2011).
Notably, the p53-family member p73 controls the expression of
miR-34a, which in turns targets mRNA encoding synaptic
proteins (Agostini et al, 2011). This is relevant for neuronal
development and plasticity. Given the limited evidence avail-
able we can only speculate that the miR-34 family controls
several developmental and age-related metabolic pathways.
Conceivably the targets of miR-34 are multiple and their
functionsmayvarytemporallyandimpacttheagingprocessand
disease.
miR-107 in Alzheimer’s disease
Expression of miR-107 decreases in Alzheimer’s patients brains
(Wang et al, 2008). Validation studies further conﬁrmed that
miR-107 levels are reduced in Alzheimer’s disease brain
neocortex (Nelson & Wang, 2010). As for miR-34c, miR-107
seems to regulate BACE1 levels (Wang et al, 2008). However,
miR-107 has another relevant substrate linked to neurodegen-
eration: progranulin (Wang et al, 2010b). In traumatic brain
injury a decreased level of miR-107 correlates with an increase
in progranulin. Conversely, progranulin deﬁciency is linked to
some forms of frontotemporal dementia (FTD), a major early
onset age-dependent neurodegerative disease. Thus in FTD
decreased levels of miR-107 may be beneﬁcial to restore
progranulin levels. Of note, recent ﬁndings indicate that miR-
29b also negatively regulates progranulin levels (Jiao et al,
2010).
Let-7 in neural stem cells
The Let-7 family has widespread effects on development and
adult model organisms and mammalian cells. This is not
surprising in view of recent ﬁndings that let-7 biogenesis is
under multiple post-transcriptional controls including miRNA
regulation of let-7 biogenesis (i.e. transcripts other than mRNA
can be miRNA targets including pri-miRs such as pri-let-7;
Zisoulis et al, 2012).
Let-7 was shown to control neural stem cell functions
(Nishino et al, 2008; Tzatsos & Bardeesy, 2008) and affect
cytokine secretion (Iliopoulos et al, 2009). Let-7 targets Hmga2,
which promotes neural stem cell self-renewal in young but not
old mice by reducing p16Ink4a and p19Arf expression (Nishino
et al, 2008) and the stemness gene lin28. Let-7 has been shown
to control aging of the Drosophila testis stem-cell niche and to
mediate the age-dependent decrease in the IGF-II messenger
RNA binding protein Imp leading to age-dependent decline
in germline stem cells (Toledano et al, 2012). Premature
senescence was also observed in ﬁbroblasts after overexpres-
sion of let-7b, which downregulates EZH2 (Tzatsos et al, 2011).
Another key target process for the let-7 miRNAs is metabolic
regulation. Downregulation of Lin28a and Lin28b, or over-
expression of let-7 in muscle causes insulin resistance and
impaired glucose tolerance. The data presented in this study not
only highlighttheroleoftheLin28a/b andlet-7asmodulators of
glucose metabolism, but also pose the question on how
accumulation of let-7 in aging tissues may contribute to the
systemic insulin resistance that accompanies aging. The role
of let-7 in diseases like cancer is widely studied. However,
evidence for a role in neurodegeneration is yet missing. In C.
elegans, the amyloid precursor protein apl-1 (homologue to the
human APP) is controlled by let-7 (Niwa et al, 2008), which is
downregulated during development. A role in mammalian cells
would be interesting in view of the self-modulation of let-7
activity.
Conclusion and outlook
In conclusion, ample evidence suggests that miRNAs are
deregulated during aging and some miRNAs have been
implicated in age-associated decline of organ functions. Aging
may induce general miRNA patterns that are similar for all
organs. In contrast, miR-29 is differentially regulated and
augmented in the aging vasculature or the heart, whereas it is
suppressed in age-associated neurodegenerative diseases. Such
an organ speciﬁc regulation is challenging when considering to
therapeutically target miRNAs to prevent or ameliorate age-
associated disease. For the potential development of therapeutic
miRNA targeting strategies, it is furthermore of critical
importance to understand whether the deregulated miRNAs
during agingarecauses oreffectors oftheage-associateddisease
or may even act as compensatory feed-back loops. The issue is
further complicated by the understanding that miRNA are
involved in more complex regulatory pathways in competition
with other competitive endogenous RNAs (ceRNA) including
pseudogenes and long non-coding RNAs (lncRNAs; Salmena
et al, 2011). Given that such interactions may likely depend on
the number of molecules of each interacting species, new
models taking into account quantitative biology will be required
to understand network modulation and ﬁnally develop
therapeutic interventions. We believe that functional investiga-
tion of miRNAs and their interacting partners will open new
perspectives for the understanding and the treatment of age-
related disease processes.
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Pending issues
Further identification and characterization of age-regulated
miRNAs.
Establishment of functions and therapeutic strategies in age-related
disease models.
Establishment of strategies to target miRNAs for chronic long term
treatment – this likely requires cell-type specific delivery in case of
miRNAs that have different functions in tissues/cells.
Understanding of the complex interactions with other competitive
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